Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial

Affiliations

• ¹ Department of Radiotherapy, Gustave Roussy, Villejuif, France; Kremlin-Bicêtre Medical Faculty, Paris-Sud University, France; INSERM 1030 Molecular Radiotherapy, France.
• ² Department of Radiotherapy, Institut régional du Cancer de Montpellier (ICM) - Val d'Aurelle, Montpellier, France.
• ³ Department of Biostatistics, Gustave Roussy, Villejuif, France.
• ⁴ Department of Radiotherapy, Institut Curie, Paris, France.
• ⁵ Department of Radiotherapy, Centre Léon Bérard, Lyon, France.
• ⁶ Department of Radiotherapy, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
• ⁷ Department of Medical Oncology, Gustave Roussy, Villejuif, France.
• ⁸ Unicancer, Paris, France.
• ⁹ Department of Radiotherapy, Saint Gregoire, France.
• ¹⁰ Department of Radiotherapy, Institut Bergonié, Bordeaux, France.
• ¹¹ Department of Radiotherapy, Gustave Roussy, Villejuif, France.
• ¹² Department of Radiotherapy, Gustave Roussy, Villejuif, France; Kremlin-Bicêtre Medical Faculty, Paris-Sud University, France; INSERM 1030 Molecular Radiotherapy, France. Electronic address: eric.deutsch@gustaveroussy.fr.